NOT-CA-18-026: Notice of Clarification on Award Project Period for PAR-17-003 "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)"

Notice of Clarification on Award Project Period for PAR-17-003 "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)"

Notice Number: NOT-CA-18-026

Key Dates
Release Date: December 13, 2017

Related Announcements
PAR-17-003

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to clarify the Award Project Period information in Funding Opportunity Announcement (FOA) PAR-17-003, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01).

The following specific changes are implemented:

Section II. Award Information

Award Project Period

Currently reads:
The parent grant must be active when the application is submitted. There must be a minimum two years of support remaining on the parent award (not to include a no cost extension) at the estimated time of award.

Modified to read (in italics)

The parent grant must be active when the application is submitted and there must be a minimum one year of support remaining on the parent award (not to include a no cost extension) at the estimated time of award. The supplement award period cannot exceed the parent R01 award period.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kelly Y. Kim, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7811
Email: kimke@mail.nih.gov